Advertisement
Research ArticleArticle

Efficient High-Throughput Screening by Endoplasmic Reticulum Ca2+ Measurement to Identify Inhibitors of Ryanodine Receptor Ca2+-Release Channels

Takashi Murayama, Nagomi Kurebayashi, Mari Ishigami-Yuasa, Shuichi Mori, Yukina Suzuki, Ryunosuke Akima, Haruo Ogawa, Junji Suzuki, Kazunori Kanemaru, Hideto Oyamada, Yuji Kiuchi, Masamitsu Iino, Hiroyuki Kagechika and Takashi Sakurai
Molecular Pharmacology July 2018, 94 (1) 722-730; DOI: https://doi.org/10.1124/mol.117.111468

Abstract

Genetic mutations in ryanodine receptors (RyRs), Ca2+-release channels in the sarcoplasmic reticulum essential for muscle contractions, cause various skeletal muscle and cardiac diseases. Because the main underlying mechanism of the pathogenesis is overactive Ca2+ release by gain-of-function of the RyR channel, inhibition of RyRs is expected to be a promising treatment of these diseases. Here, to identify inhibitors specific to skeletal muscle type 1 RyR (RyR1), we developed a novel high-throughput screening (HTS) platform using time-lapse fluorescence measurement of Ca2+ concentrations in the endoplasmic reticulum (ER) ([Ca2+]ER). Because expression of RyR1 carrying disease-associated mutation reduces [Ca2+]ER in HEK293 cells through Ca2+ leakage from RyR1 channels, specific drugs that inhibit RyR1 will increase [Ca2+]ER by preventing such Ca2+ leakage. RyR1 carrying the R2163C mutation and R-CEPIA1er, a genetically encoded ER Ca2+ indicator, were stably expressed in HEK293 cells, and time-lapse fluorescence was measured using a fluorometer. False positives were effectively excluded by using cells expressing wild-type (WT) RyR1. By screening 1535 compounds in a library of well characterized drugs, we successfully identified four compounds that significantly increased [Ca2+]ER. They include dantrolene, a known RyR1 inhibitor, and three structurally different compounds: oxolinic acid, 9-aminoacridine, and alexidine. All the hit compounds, except for oxolinic acid, inhibited [3H]ryanodine binding of WT and mutant RyR1. Interestingly, they showed different dose dependencies and isoform specificities. The highly quantitative nature and good correlation with the channel activity validated this HTS platform by [Ca2+]ER measurement to explore drugs for RyR-related diseases.

Introduction

Ryanodine receptors (RyRs) are Ca2+-release channels in the sarcoplasmic reticulum (SR) of skeletal and cardiac muscles that play a central role in muscle contractions (Fill and Copello, 2002; Bers, 2004). Genetic mutations in the skeletal muscle isoform [type 1 RyR (RyR1)] cause several diseases, including malignant hyperthermia (MH) and central core disease (Robinson et al., 2006; Treves et al., 2008), and those in the cardiac isoform [type 2 RyR (RyR2)] are associated with various arrhythmogenic heart diseases (Betzenhauser and Marks, 2010; Priori and Chen, 2011). The underlying mechanism of most of these diseases is a gain-of-function of the channel. Hyperactivation of RyR channels may cause dysregulation of Ca2+ release or Ca2+ leakage that triggers disease phenotypes. Therefore, drugs inhibiting RyR channels are expected to be a promising treatment of such diseases.

In terms of RyR1-related diseases, dantrolene is the only approved drug for MH, which prevents large amounts of Ca2+ release caused by volatile anesthetics (Kolb et al., 1982). However, dantrolene is not approved for central core disease due to its side effects in chronic administration. For arrhythmogenic diseases associated with RyR2, several drugs, such as carvedilol (Zhou et al., 2011), flecainide (Watanabe et al., 2009), and S107 (Lehnart et al., 2008), have been proposed to prevent the hyperactivity of mutated RyR2. However, most of these drugs also interact with molecules other than RyR, causing undesired effects. Therefore, there is an urgent need to develop or identify specific RyR inhibitors.

High-throughput screening (HTS) is a powerful method for rapid evaluation of thousands to millions of chemical compounds, which greatly accelerates drug discovery. To effectively identify true hit compounds, establishment of an appropriate HTS platform for the target molecule is critically important. For the success of an RyR-directed HTS platform, it is essential to quantitatively evaluate the channel activity under physiologic conditions. We have recently investigated genotype-phenotype correlations of the channel activity of RyR1 carrying various disease-associated mutations that were expressed in HEK293 cells (Murayama et al., 2015, 2016). We found that the Ca2+ concentration in the endoplasmic reticulum (ER) ([Ca2+]ER) of the mutants was inversely correlated with their channel activity and, thus, was expected to be an excellent quantitative index for an HTS platform to explore RyR inhibitors.

In this study, we developed and validated a novel HTS platform to identify RyR1 inhibitors using time-lapse fluorescence [Ca2+]ER measurements in HEK293 cells expressing mutant RyR1s. By screening a chemical library of well characterized drugs (1535 compounds), we successfully identified dantrolene and three other compounds (oxolinic acid, 9-aminoacridine, and alexidine) that specifically prevent Ca2+ leakage to increase [Ca2+]ER in cells expressing mutant RyR1s. The hit compounds exhibited different dose dependencies and isoform specificities, suggesting that they inhibit RyR1 by different mechanisms. The highly quantitative nature and good correlation with the channel activity validate this novel HTS platform to explore drugs for RyR-related diseases.

Materials and Methods

Generation of Stable and Inducible HEK293 Cell Lines.

HEK293 cells stably and inducibly expressing wild-type (WT) and the R2163C mutant of RyR1 (Murayama et al., 2016) or WT RyR2 (Uehara et al., 2017) were generated as described previously. For the HTS assay using [Ca2+]ER measurement, cDNA for R-CEPIA1er (Suzuki et al., 2014) was transfected in these cells using the Jump-In system (Thermo Fisher Scientific, Waltham, MA), and clones with suitable fluorescence were selected and used for further experiments. Cells were cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal calf serum, 2 mM l-glutamine, 15 µg/ml blasticidin, 100 µg/ml hygromycin, and 400 µg/ml G418. In the case of other disease-associated RyR1 mutants (G342R, R2435H, and L4824P), R-CEPIA1er was transiently expressed using a baculovirus vector (Uehara et al., 2017).

Time Lapse [Ca2+]ER Measurements.

Time-lapse [Ca2+]ER measurements were performed using the FlexStation II fluorometer (Molecular Devices, San Jose, CA). HEK293 cells were seeded on 96-well, flat, clear-bottom black microplates (#3603; Corning, New York, NY) at a density of 2 × 104 cells/well. One day after seeding, expression of RyR1 was induced by addition of doxycycline (2 µg/ml) to the culture medium. After 24–28 hours of induction, the culture medium was replaced with 90 µl of HEPES-buffered Krebs solution (140 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 11 mM glucose, and 5 mM HEPES, pH 7.4), and the microplates were placed in the FlexStation II fluorometer, which was preincubated at 37°C. R-CEPIA1er signals, which were excited at 560 nm and emitted at 610 nm, were captured every 10 seconds for 300 seconds. Sixty microliters of the compounds dissolved in HEPES-Krebs solution (25 µM) was applied to the cells 100 seconds after starting. The fluorescence change induced by the compounds was expressed as F/F0, in which averaged fluorescence intensity of the last 100 seconds (F) was normalized to that of the initial 100 seconds (F0). We screened 1535 well characterized drugs owned by Tokyo Medical and Dental University (TMDU) chemical compound library at 10 µM (Yoshizaki et al., 2017).

HTS Data Analysis.

Assay quality was determined based on positive (10 µM dantrolene) and negative [0.1% dimethylsulfoxide (DMSO)] controls, as indexed by the Z′ factor:Embedded Image(1)where σP and σN are the S.D.s of positive and negative controls, and μP and μN are the means of positive and negative controls, respectively. A compound was considered a hit if it increased F/F0 by >3 S.D.s relative to negative control samples. The hit selection threshold of three S.D.s is typical for normally distributed HTS data in which 0.27% of the readings are expected to fall outside of this limit.

[3H]Ryanodine Binding.

The assay was carried out as described previously (Murayama et al., 2015, 2016) with some modifications. In brief, microsomes prepared from HEK293 cells stably expressing the R2163C mutant of RyR1 or WT RyR2 were incubated with 5 nM [3H]ryanodine for 2 hours at 37°C (for RyR1) or 25°C (for RyR2) in medium containing 0.17 M NaCl, 20 mM 3-morpholino-2-hydroxypropanesulfonic acid (MOPSO) (pH 7.0), 2 mM dithiothreitol, 1 mM β,γ-methyleneadenosine 5′-triphosphate, 1 µM calmodulin, and various concentrations of free Ca2+ buffered with 10 mM EGTA. Free Ca2+ concentrations were calculated using WEBMAXC STANDARD (http://web.stanford.edu/∼cpatton/webmaxcS.htm) (Bers et al., 2010). Protein-bound [3H]ryanodine was separated by filtration through polyethyleneimine-treated glass filters (Filtermat B, PerkinElmer, Waltham, MA) using a Micro 96 Cell Harvester (Skatron Instruments, Lier, Norway). Nonspecific binding was determined in the presence of 20 μM unlabeled ryanodine.

Measurement of ATPase Activity of SERCA.

Sarcoplasmic reticulum (SR) vesicles were obtained from white skeletal muscle of rabbit hind legs as described by Eletr and Inesi (Eletr and Inesi, 1972). Ca2+-dependent ATPase activity of SERCA was measured at 25°C by a coupled enzyme assay (Madden et al., 1979) using grating microplate reader SH8100Lab (CORONA). 6.4 μg of the SR vesicles was incubated with the assay buffer (60 mM 3-Morpholinopropanesulfonic acid, pH 7.0, 120 mM KCl, 6 mM MgCl2, 1 mM EGTA, 5 mM NaN3, 0.2 mM NADH, 0.5 mM phosphoenol pyruvate, 5.2 IU of lactate dehydrogenase, 5.2 IU of pyruvate kinase, 0.01 mM A23187, and CaCl2 added to set free [Ca2+] to the desired values) containing 10 μM of each compound for 5 min. After the incubation, the assay was started upon the addition of ATP at a final concentration of 2 mM. The ATPase activity was monitored by following the decrease of NADH absorbance (A340) for 5 min.

Statistics.

Data are presented as the mean ± S.D. Statistical analysis was performed using Prism 6 (GraphPad Software, Inc., La Jolla, CA). One-way analysis of variance, followed by Dunnett’s test, was performed to compare multiple groups. Statistical significance was defined as P < 0.05 compared with DMSO (negative control).

Results

Development and Validation of the HTS Platform for RyR Inhibitors Using [Ca2+]ER Measurements.

The concept of the HTS platform for RyR1 inhibitors by [Ca2+]ER measurements is as follows. [Ca2+]ER is generally determined by the balance between Ca2+ release via the Ca2+-release pathways and Ca2+ uptake by sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA) Ca2+ pumps. We found that expression of WT RyR1 in HEK293 cells does not significantly change [Ca2+]ER because of its very low Ca2+-release activity at resting intracellular Ca2+ concentrations ([Ca2+]i) (Murayama et al., 2015, 2016). Expression of RyR1 carrying disease-associated mutations, in contrast, reduces [Ca2+]ER to inversely correlate with their channel activity (Supplemental Fig. 1). This is explained by Ca2+ leakage from the ER at resting [Ca2+]i via the mutant RyR1 channels that overcomes Ca2+ uptake. Thus, [Ca2+]ER is an excellent quantitative indicator of the RyR1 activity. If a drug inhibits RyR1, then Ca2+ leakage will be prevented to increase [Ca2+]ER in the mutant RyR1 cells by means of Ca2+ uptake (Fig. 1A). This provides an efficient HTS platform for screening of the RyR1 inhibitors. The drug, in contrast, will not increase [Ca2+]ER in the WT RyR1 cells, because [Ca2+]ER is not reduced (Fig. 1B). In this respect, WT RyR1 cells should be used as a negative control to effectively exclude false positives.

Fig. 1.
Fig. 1.

Strategy and establishment of HTS platform for RyR1 inhibitors using [Ca2+]ER measurement. (A and B) Schematic drawings of strategy of HTS platform using [Ca2+]ER measurement. (A) In the mutant RyR1 cells, [Ca2+]ER is reduced because of Ca2+ leakage via the RyR1 channel. Drugs inhibiting RyR1 will prevent Ca2+ leakage and increase [Ca2+]ER. (B) In the WT RyR1 cells, drugs inhibiting the RyR1 channel will not change [Ca2+]ER, because [Ca2+]ER in the WT RyR1 cells is not reduced because of very small Ca2+ leakage. (C and D) Time-lapse R-CEPIA1er fluorescence measurement using a FlexStation II fluorometer with HEK293 cells expressing R2163C (C) or WT (D) RyR1. DMSO (filled gray circles), 10 µM dantrolene (filled color circles), or 10 mM caffeine (open color circles) was applied at 100 seconds (arrows). In R2163C RyR1 cells, dantrolene increased the R-CEPIA1er fluorescence, whereas caffeine decreased it. In the WT RyR1 cells, dantrolene did not change the R-CEPIA1er fluorescence, whereas caffeine markedly decreased it. (E) Effect of thapsigargin, a SERCA Ca2+ pump inhibitor, on the fluorescence change (F/F0) of R2163C (orange) and WT (green) RyR1 cells. One micromolar thapsigargin was applied at 100 seconds (arrows). (F) Summary of fluorescence change (F/F0) of R2163C (orange) and WT (green) RyR1 cells by various drugs. F/F0 was obtained by normalizing the averaged fluorescence for the last 100 seconds (F) to that for the first 100 seconds (F0). Dotted line denotes 1 F/F0, i.e., no fluorescent change by the drug. Caffeine (Caf; 10 mM) and thapsigargin (TG; 1 µM) reduced F/F0 to a similar level. Dantrolene (Dan) and tetracaine (Tet; 1 mM) greatly increased F/F0 in R2163C RyR1 cells, whereas ruthenium red (RuR; 10 µM) and neomycin (Neo; 10 µM) did not. Data are the mean ± S.D. (n = 8). *P < 0.05 compared with DMSO (one-way analysis of variance with Dunnett’s test).

To establish the HTS platform, we generated HEK293 cell lines that stably expressed WT or mutant RyR1s. R2163C was chosen as a typical mutation, because the [Ca2+]ER of R2163C-mutant cells is reduced to one-third of that in WT cells (Murayama et al., 2016) (Supplemental Fig. 1). Then, R-CEPIA1er, a genetically encoded ER-targeted red fluorescent Ca2+ indicator (Suzuki et al., 2014), was stably expressed in RyR1-HEK293 cells. Because R-CEPIA1er is a single wavelength excitation Ca2+ indicator, it is compatible with standard fluorometers. Time-lapse fluorescence measurements were performed using a FlexStation II fluorometer with 96-well plates. We initially examined the effects of dantrolene and caffeine, known RyR1 inhibitor and activator, respectively, on the R-CEPIA1er fluorescence of the R2163C and WT RyR1 cells. R-CEPIA1er was excited at 560 nm, and emission at 610 nm was captured every 10 seconds for 300 seconds. Compounds were applied at 100 seconds after starting. In the R2163C RyR1 cells, application of 10 µM dantrolene gradually increased the fluorescence intensity over time and reached a plateau at 200 seconds or later (Fig. 1C). Conversely, 10 mM caffeine decreased the fluorescence. In WT RyR1 cells, dantrolene did not change the fluorescence intensity, but 10 mM caffeine rapidly and markedly decreased the fluorescence (Fig. 1D). Quantitative results are summarized in Fig. 1F, in which the fluorescence change (F/F0) induced by compounds was determined by normalizing the averaged fluorescence intensity for the last 100 seconds (F) to that for the initial 100 seconds (F0). The different responses of the R2163C and WT RyR1 cells to dantrolene and caffeine were consistent with the aforementioned idea. In addition, a SERCA inhibitor, thapsigargin (1 μM), reduced the fluorescence for both cells to a level similar to that by caffeine (Fig. 1E), confirming the importance of SERCA Ca2+ pumps in maintaining [Ca2+]ER. We also investigated other known RyR1 inhibitors: tetracaine (Laver and van Helden, 2011), ruthenium red (Ma, 1993), and neomycin (Mead and Williams, 2004) (Fig. 1F). Tetracaine (1 mM) increased F/F0 in the R2163C, but not WT, RyR1 cells. In contrast, ruthenium red (10 μM) and neomycin (10 μM) had no effects. These results are reasonably explained by membrane permeability of the inhibitors. Ruthenium red and neomycin are least permeable through the cell membrane (Brodie and Reed, 1991). Thus, [Ca2+]ER measurement successfully detected known membrane-permeable RyR1 inhibitors, which strongly supports usefulness of our HTS platform.

To quantitatively validate the assay system, we then determined the coefficient of variation (CV) and Z′ factor. Histograms of F/F0 for the R2163C RyR1 cells showed that fluorescence changed by dantrolene (μ = 1.79 and σ = 0.12) was perfectly separated from that changed by DMSO (μ = 0.95 and σ = 0.05) (Fig. 2A). CV values for dantrolene and DMSO were 0.07 and 0.05, respectively, which satisfied the criteria for HTS (CV <0.1). The Z′ factor was calculated by eq. 1 as 0.40 (see Materials and Methods), which was within the acceptable range. In the WT RyR1 cells, in contrast, the fluorescence change induced by 10 µM dantrolene (μ = 1.00 and σ = 0.05) overlapped with that induced by DMSO (μ = 0.97 and σ = 0.05) (Fig. 2B). Dose-response assay revealed that F/F0 was increased by dantrolene in a dose-dependent manner, and the results were well fitted by the Michaelis-Menten equation with an EC50 of 0.06 µM (Fig. 2C). Taken together, these results indicate that our HTS platform has excellent detection sensitivity.

Fig. 2.
Fig. 2.

Validation of the HTS platform using [Ca2+]ER measurement. (A and B) Histograms of F/F0 induced by DMSO (n = 144) and dantrolene (n = 144) in R2163C RyR1 cells (A) or WT RyR1 cells (B). (C) Dose-dependent effect of dantrolene on F/F0 in R2163C (orange, n = 7) and WT (green, n = 4) RyR1 cells. Data are the mean ± S.D. Note that dantrolene increased F/F0 in R2163C RyR1 cells in a dose-dependent manner with an EC50 of 0.06 µM.

Screening of a Chemical Compound Library by [Ca2+]ER Measurements.

Using this HTS platform by [Ca2+]ER measurements, we screened a TMDU chemical compound library of well characterized drugs (1535 compounds) at 10 µM concentrations. The overall results with the R2163C and WT RyR1 cells in duplicate assays are shown in Fig. 3, A and B, respectively. Based on the finding that RyR1 inhibitors did not increase the fluorescence intensity of the WT RyR1 cells, eight compounds that increased F/F0 in the WT RyR1 cells by >3 S.D.s were excluded as false positives, all of which exhibited autofluorescence excited by 560 nm (Supplemental Table 1). A threshold for hit compounds was set at +3 S.D.s for DMSO in the R2163C cells, which was expected to cover ∼0.14% of total compounds. We successfully identified four compounds (#1–#4) that greatly increased the fluorescence of the R2163C RyR1 cells (F/F0 >1.5), but not that of WT RyR1 cells (Fig. 3, A and B). They were oxolinic acid (#1), 9-aminoacridine (#2), dantrolene (#3), and alexidine (#4) (Fig. 3C). The fact that dantrolene was yielded as a hit strongly validated our HTS platform using [Ca2+]ER measurements.

Fig. 3.
Fig. 3.

HTS results. A TMDU chemical compound library of well characterized drugs (1535 compounds, 10 μM) was screened in HEK293 cells expressing R2163C (A) or WT (B) RyR1. Four compounds (1–4, red) were identified as hits using a threshold of +3 S.D.s (F/F0 = 1.15, dotted line). Data are the mean of duplicate screens. Dotted line denotes 1 F/F0. (C) Structures of the hit compounds: 1) oxolinic acid, 2) 9-aminoacridine, 3) dantrolene, and 4) alexidine.

Dose Dependency and Subtype Specificity of Hit Compounds.

To further characterize the hit compounds, we investigated dose effects on [Ca2+]ER using the same assay conditions as the HTS. The hit compounds exhibited different dose effects on the R2163C RyR1 cells (Fig. 4A). Dantrolene showed the highest potency (EC50 ∼0.05 µM), followed by oxolinic acid (EC50 ∼0.5 µM). They both exhibited apparent saturation of [Ca2+]ER. 9-Aminoacridine and alexidine were much less potent (EC50 >10 µM), but their maximum activities (i.e., efficacy) were 2-fold higher than those of dantrolene or oxolinic acid. All compounds had no apparent effects on the WT RyR1 cells up to 30 µM (Fig. 4B).

Fig. 4.
Fig. 4.

Dose dependency and isoform specificity of hit compounds. (A–C) Dose-dependent effects of hit compounds (0.01–30 µM) on [Ca2+]ER measurements in HEK293 cells expressing R2163C (A), WT RyR1 (B), or WT RyR1 in the presence of 5 mM caffeine (C). Data are the mean ± S.D. (n = 8 for R2163C, n = 6 for WT, and n = 4 for WT + caffeine). (D) Effects of hit compounds (30 µM) on the [Ca2+]ER of cells with RyR1 carrying disease-associated mutations (G342R, R2435H, and L4824P). Data are the mean ± S.D. (n = 4). (E) Dose-dependent effects of hit compounds (0.01–30 µM) on [Ca2+]ER measurements in HEK293 cells expressing WT RyR2. Data are the mean ± S.D. (n = 4). Dotted line denotes 1 F/F0. *P < 0.05 compared with DMSO (one-way analysis of variance with Dunnett’s test). 9AA, 9-aminoacridine; Ale, alexidine; Dan, dantrolene; Oxo, oxolinic acid.

Because hit compounds were identified using the R2163C mutant, a concern was that the inhibitory effect might be specific to this mutation. Therefore, we examined whether hit compounds are effective on WT and other mutant RyR1s. Because WT RyR1 does not reduce [Ca2+]ER in the resting state (see Fig. 1), we were forced to reduce [Ca2+]ER in the WT RyR1 cells by caffeine (Supplemental Fig. 2). In the presence of 5 mM caffeine, four hit compounds successfully increased [Ca2+]ER of the WT RyR cells in a dose-dependent manner (Fig. 4C), as in case of the R2163C RyR1 cells (Fig. 4A). In addition, all four hit compounds at 30 µM significantly increased [Ca2+]ER of cells expressing RyR1 carrying MH mutations in different regions: G342R, R2435H, and L4824P, all of which exhibit gain-of-function phenotype (Murayama et al., 2015, 2016) (Fig. 4D). These results confirmed that the hit compounds are also effective on WT and the other mutant RyR1s. We also tested isoform specificity of the hit compounds using HEK293 cells stably expressing RyR2, an RyR isoform in the heart (Fig. 4E). Dantrolene and oxolinic acid had no effects on RyR2 up to 30 µM, suggesting that the two compounds specifically inhibit RyR1. In contrast, 9-aminoacridine and alexidine greatly increased [Ca2+]ER at 30 µM, an indication of inhibition of both RyR1 and RyR2.

Effects of Hit Compounds on [3H]Ryanodine Binding.

To validate whether hit compounds directly inhibit RyR1, we examined the effects of hit compounds on [3H]ryanodine binding. Since ryanodine binds to only an open RyR channel, binding of ryanodine reflects activity of the RyR channel (Meissner, 1994; Ogawa, 1994). We initially determined Ca2+-dependent [3H]ryanodine binding with microsomes isolated from the R2163C RyR1 cells (Fig. 5, A and B). Without compounds, the R2163C RyR1 exhibited biphasic Ca2+ dependency with a peak at about 10 µM Ca2+ (Fig. 5A). Dantrolene reduced the peak binding with a slight rightward shift of the curve for activation. Unexpectedly, oxolinic acid had no effects on the [3H]ryanodine binding. 9-Aminoacridine and alexidine similarly inhibited the binding by reducing the peak value without affecting Ca2+ dependency (Fig. 5B). Dose-dependent inhibition at 1 μM Ca2+ revealed different potencies of the hit compounds (Fig. 5C). The dose dependencies of the hit compounds, except for oxolinic acid, were consistent with those determined by [Ca2+]ER measurements (see Fig. 4A). We also examined the effects of hit compounds on [3H]ryanodine binding of WT RyR1. Because WT RyR1 exhibits much lower [3H]ryanodine binding than R2163C (Murayama et al., 2015, 2016), 10 mM caffeine was added to accelerate the channel activity. Under this condition, all hit compounds, except for oxolinic acid, effectively inhibited [3H]ryanodine binding (Fig. 5D). Taken together, these results strongly indicate that the three of the hit compounds (dantrolene, 9-aminoacridine, and alexidine) directly inhibit RyR1. The fact that oxolinic acid had no effects on [3H]ryanodine binding raises the possibility that the drug might inhibit RyR1 through target molecules other than RyR1 or act as a pore blocker that does not affect [3H]ryanodine binding. The effects of hit compounds (30 µM) were also examined with RyR2 (Fig. 5E). Whereas 9-aminoacridine and alexidine significantly reduced [3H]ryanodine binding to WT RyR2, dantrolene and oxolinic acid had no effects, which was consistent with the results of [Ca2+]ER measurements (see Fig. 4E).

Fig. 5.
Fig. 5.

Effects of hit compounds on [3H]ryanodine binding. (A and B) Ca2+-dependent [3H]ryanodine binding to R2163C RyR1 in the presence of hit compounds (30 µM). Data are the mean ± S.D. (n = 4). (C) Dose-dependent inhibition of R2163C RyR1 by hit compounds at 1 µM Ca2+. Data are the mean ± S.D. (n = 4). (D) Effect of hit compounds (30 µM) on [3H]ryanodine binding to WT RyR1 in the presence of 10 mM caffeine at 1 µM Ca2+. Data are the mean ± S.D. (n = 4). (E) Effect of hit compounds (30 µM) on [3H]ryanodine binding to WT RyR2 at 10 µM Ca2+. Data are the mean ± S.D. (n = 4). *P < 0.05 compared with DMSO (one-way analysis of variance with Dunnett’s test). 9AA, 9-aminoacridine; Ale, alexidine; Dan, dantrolene; Oxo, oxolinic acid.

Effects of Hit Compounds on the Ca2+ Pump Activity.

As described earlier, [Ca2+]ER is determined by the balance between Ca2+-release pathways and Ca2+ uptake by SERCA Ca2+ pumps. Therefore, if a drug activates Ca2+ pumps, then [Ca2+]ER will increase. We tested this possibility by measuring Ca2+-ATPase activity using skeletal muscle microsomes. Dantrolene, oxolinic acid, and 9-aminoacridine at 10 µM had no effects on the Ca2+-ATPase activity (Fig. 6). This result excluded the possibility of Ca2+ pump activation by these drugs. To our surprise, alexidine (10 µM) strongly inhibited the Ca2+-ATPase activity at all examined Ca2+ concentrations (Fig. 6).

Fig. 6.
Fig. 6.

Effects of hit compounds on Ca2+-ATPase activity. (A) Ca2+-dependent Ca2+-ATPase activity of SERCA was determined using skeletal muscle microsomes in the presence of 10 µM hit compounds. Data are the mean ± S.D. (n = 3). (B) Ca2+-ATPase activity under treatments with hit compounds at 100 µM Ca2+ (n = 3). One hundred percent denotes the activity under DMSO treatment. *P < 0.05 compared with DMSO (one-way analysis of variance with Dunnett’s test). 9AA, 9-aminoacridine; Ale, alexidine; Dan, dantrolene; Oxo, oxolinic acid.

Discussion

Hyperactivation of the RyR channel is implicated in the pathology of several muscular and arrhythmogenic heart diseases (Robinson et al., 2006; Treves et al., 2008; Betzenhauser and Marks, 2010; Priori and Chen, 2011). Therefore, chemical compounds that inhibit the RyR channel are expected to be potentially therapeutic for these diseases. Several methods are used to evaluate RyR1 channel activity, such as single channel current recordings in lipid bilayers, [3H]ryanodine binding to isolated SR vesicles, and Ca2+-release measurements in isolated SR or skinned fibers (Meissner, 1994; Ogawa, 1994). However, these methods are difficult to apply to HTS for RyR-directed drugs because of their complicated procedures or requirement of a specific apparatus.

Based on the finding that [Ca2+]ER is inversely correlated with the channel activity of the RyR1 mutants in HEK293 cells (Murayama et al., 2015, 2016) (Supplemental Fig. 1), we developed a novel HTS platform for RyR1 inhibitors by time-lapse fluorescence measurement of [Ca2+]ER using R-CEPIA1er, a genetically encoded Ca2+ indicator (Fig. 1). Indeed, our HTS platform perfectly separated negative (DMSO) and positive (10 µM dantrolene) controls with excellent CV values (Fig. 2). By screening a TMDU chemical compound library of 1535 well characterized drugs, we identified four hit compounds (dantrolene, oxolinic acid, 9-aminoacridine, and alexidine) (Fig. 3). The fact that dantrolene was yielded as a hit strongly validated our HTS platform. All of the hit compounds were also effective on WT and other mutant RyR1s (Fig. 4). Three of the hit compounds, except for oxolinic acid, inhibited [3H]ryanodine binding of RyR1, indicating that they directly inhibit RyR1 (Fig. 5). Our method is superior to existing methods as follows. First, it is quite easy because it simply measures [Ca2+]ER in cells using a standard fluorometer without any pretreatment. Second, [Ca2+]ER measurement evaluates the channel activity under the resting [Ca2+]i that mimics the situation in vivo. Finally, our method measures the steady-state level of [Ca2+]ER, which is more stable and reproducible than the method measuring transient [Ca2+]i changes that are triggered by Ca2+ release via RyR1.

Fluorescence measurements are generally affected by compounds that emit or absorb fluorescence. In our method, the rate of false positives with autofluorescence was as low as 0.5% (8 out of 1535 compounds) (Supplemental Table 1). A long excitation wavelength for R-CEPIA1er (560 nm) may contribute to the low rate of false positives. [Ca2+]ER is generally influenced by both Ca2+-uptake pathways (i.e., SERCA Ca2+ pumps) and Ca2+-release pathways (i.e., RyRs, inositol 1,4,5-trisphosphate receptors, and other ER Ca2+-leak channels). Therefore, it seems possible that screening by [Ca2+]ER measurements will also identify modulators for these pathways other than RyR1. However, all of the hit compounds targeted to RyR1. This high specificity may be reasonably explained by the fact that ER Ca2+-leak activity from the exogenously expressed mutant RyR1 channels is much greater than that via the endogenous Ca2+-leak pathways in HEK293 cells (Fig. 1). A general concern for drug screening by the mutant protein is a biased result, e.g., hit compounds affect only the mutant but not the WT protein. However, all four hit compounds were effective not only on R2163C RyR1 but also on WT and the other mutant RyR1s (Fig. 4). Thus, use of the mutant RyR1 may not have a serious impact on the results, although we cannot exclude the possibility of some bias.

Recently, Rebbeck et al. (2017) reported an excellent HTS strategy to identify RyR modulators using time-resolved fluorescence resonance energy transfer. By measuring changes in fluorescence resonance energy transfer signals between calmodulin and FKBP12.6 in the RyR1 channel, they successfully identified six compounds that activate (cefatrizine, cefixime, disulfiram, ebselen, and tacrolimus) or inhibit (chloroxine) RyR1. Among three compounds (chloroxine, disulfiram, and tacrolimus) in our library, disulfiram and tacrolimus exhibited significant reductions of [Ca2+]ER (F/F0 = 0.60 and 0.70 for disulfiram and tacrolimus, respectively) in the mutant RyR1 (Supplemental Table 2). This indicates activation of the RyR1 channel, which is consistent with their conclusion. However, chloroxine exhibited a slight reduction of [Ca2+]ER (F/F0 = 0.80) in our screening (Supplemental Table 2), which is indicative of a weak activating effect. So far, the reason for this difference remains unclear. One plausible explanation is the method adopted. A comparison of the HTS results between the two strategies will provide useful information for RyR1 modulators.

Oxolinic acid is a first-generation quinolone antibiotic that has been used for urinary tract infections (Gleckman et al., 1979) and now mainly for aquaculture (Martinsen et al., 1992). It inhibits bacterial DNA gyrase (Cozzarelli, 1977). Oxolinic acid is also reported to act as a dopamine reuptake inhibitor and has stimulant effects in mice (Garcia de Mateos-Verchere et al., 1998). We found that oxolinic acid increased [Ca2+]ER of RyR1 cells, but not RyR2 cells (Fig. 4). The RyR1-specific inhibition is a great advantage for clinical use. Unexpectedly, oxolinic acid did not affect [3H]ryanodine binding to RyR1 (Fig. 5). This raises the possibility of indirect action of oxolinic acid that it inhibits RyR1 by binding to some associated molecules, which were removed from RyR1 through the preparation of microsomes used for [3H]ryanodine binding. Alternatively, oxolinic acid might act as a pore blocker which does not affect [3H]ryanodine binding. Our chemical compound library includes 18 quinolone antibiotics (first to fourth generations), but no compounds other than oxolinic acid had significant effects on [Ca2+]ER in the screening (Supplemental Table 2). The structure-function relationships will provide useful information for structural expansion of oxolinic acid.

9-Aminoacridine is a green fluorescent dye that has been used as an antimalarial and antimicrobial drug, and is now expected to be an anticancer agent (Sebestík et al., 2007). We found that 9-aminoacridine strongly inhibited [3H]ryanodine binding to RyR1 and RyR2 (Fig. 5). This result corresponds to previous reports showing that 9-aminoacridine inhibits Ca2+ release from skeletal muscle SR (Palade, 1987; Brunder et al., 1992). In our compound library, 9-aminoacridine derivatives (amsacrine, ethacridine, and mepacrine) had no effects (Supplemental Table 2). Thus, introduction of substituents of the amino group or acridine ring may decrease its activity. Alexidine is an alkyl bisbiguanide antiseptic that is used in mouthwashes to eliminate plaque-forming microorganisms (Coburn et al., 1978). It also inhibits the mitochondrial phosphatase PTPMT1 (protein tyrosine phosphatase, mitochondrial 1) (Doughty-Shenton et al., 2010) and induces apoptosis in cancer cells (Yip et al., 2006). Alexidine inhibited [3H]ryanodine binding to RyR1 and RyR2 at 10 µM or higher concentrations (Fig. 5). It also strongly inhibited Ca2+ pumps in skeletal muscle (Fig. 6). Because the other biguanides (chlorhexidine, metformin, phenformin, phenylbiguanide, and proguanil) included in our library had no effects (Supplemental Table 2), the biguanide moiety is not responsible for the inhibitory effect of alexidine.

In the current method, compounds impermeable to the cell membrane were recognized as false negatives (Fig. 1). Although the false-negative rate is unclear, this might be a potential limitation of our HTS platform. In skeletal muscle, many proteins interact with RyR1 to regulate the channel activity (Fill and Copello, 2002). Because HEK293 cells do not express such associated proteins, compounds targeted to certain factors to indirectly inhibit the RyR1 channel might not be included in our HTS platform. Coexpression of regulatory factors in our HTS platform will identify compounds more specific to “skeletal muscle RyR1.” In the current HTS of 1535 compounds, we identified four RyR1 inhibitors. By screening a large library of ∼150,000 compounds, we anticipate detection of ∼390 novel RyR1 inhibitors that may include several viable candidates for novel drugs. This would greatly expand our understanding of the pharmacology of RyR1.

Acknowledgments

We are grateful for the Laboratory of Proteomics and Biomolecular Science, Research Support Center, Juntendo University Graduate School of Medicine for their technical support. We thank Paul D. Allen (University of Leeds) for careful reading of the manuscript. We also thank Mitchell Arico from Edanz Group (www.edanzediting.com/ac) for editing a draft of the manuscript.

Authorship Contributions

Participated in research design: Murayama, Kurebayashi, Ishigami-Yuasa, Mori, Kagechika, Sakurai.

Conducted experiments: Murayama, Kurebayashi, Y. Suzuki, Akima, Ogawa.

Contributed new reagents or analytic tools: J. Suzuki, Kanemaru, Oyamada, Kiuchi, Iino.

Performed data analysis: Murayama, Kurebayashi, Ishigami-Yuasa, Mori, Ogawa, Kagechika, Sakurai.

Wrote or contributed to the writing of the manuscript: Murayama, Kurebayashi, Ogawa.

Note Added in Proof

Note Added in Proof—Some descriptions in the Methods section with references were accidentally not included in the Fast Forward version published April 19, 2018. The Methods and references have now been corrected.

Footnotes

    • Received December 18, 2017.
    • Accepted April 12, 2018.

  • ↵1 Current affiliation: Department of Physiology, University of California, San Francisco, California.

  • ↵2 T.M. and N.K. contributed equally to this work.

  • This work was supported in part by Japan Society for the Promotion of Science KAKENHI [Grants JP16K08507, JP15K08243, JP16H04748, and JP16K08917]; Platform Project for Supporting Drug Discovery and Life Science Research [Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)] from Japan Agency for Medical Research and Development (AMED) [Grant JP17am0101080j0001]; Practical Research Project for Rare/Intractable Diseases from AMED [Grant JP17ek0109202h0001]; Intramural Research Grant for Neurologic and Psychiatric Disorders of National Center for Neurology and Psychiatry [Grant 29-4]; the Vehicle Racing Commemorative Foundation; the Institute of Seizon and Life Sciences; the Cooperative Research Project of Research Center for Biomedical Engineering; a grant from the Institute for Environmental & Gender-specific Medicine, Juntendo University; and Program for the Strategic Research Foundation at Private Universities supported by Ministry of Education, Culture, Sports, Science and Technology, Japan.

  • The authors declare that they have no conflict of interest.

  • https://doi.org/10.1124/mol.117.111468.

  • ↵Embedded ImageThis article has supplemental material available at molpharm.aspetjournals.org.

Abbreviations

[Ca2+]ER
Ca2+ concentrations in the endoplasmic reticulum
[Ca2+]i
cytoplasmic Ca2+ concentrations
CV
coefficient of variation
DMSO
dimethylsulfoxide
ER
endoplasmic reticulum
HTS
high-throughput screening
MH
malignant hyperthermia
RyR
ryanodine receptor
RyR1
type 1 ryanodine receptor
RyR2
type 2 ryanodine receptor
SERCA
sarcoplasmic/endoplasmic reticulum Ca2+-ATPase
SR
sarcoplasmic reticulum
TMDU
Tokyo Medical and Dental University
WT
wild-type.

References

  1. ↵
    1. Bers DM
    (2004) Macromolecular complexes regulating cardiac ryanodine receptor function. J Mol Cell Cardiol 37:417–429.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Bers DM,
    2. Patton CW, and
    3. Nuccitelli R
    (2010) A practical guide to the preparation of Ca2+ buffers. Methods Cell Biol 99:1–26.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Betzenhauser MJ and
    2. Marks AR
    (2010) Ryanodine receptor channelopathies. Pflugers Arch 460:467–480.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Brodie AE and
    2. Reed DJ
    (1991) Calcium chelation induced glutathione efflux from tumor cells and prevention by ruthenium red or neomycin. Biochem Biophys Res Commun 176:276–279.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Brunder DG,
    2. Györke S,
    3. Dettbarn C, and
    4. Palade P
    (1992) Involvement of sarcoplasmic reticulum ‘Ca2+ release channels’ in excitation-contraction coupling in vertebrate skeletal muscle. J Physiol 445:759–778.
    OpenUrlPubMed
  6. ↵
    1. Coburn RA,
    2. Baker PJ,
    3. Evans RT,
    4. Genco RJ, and
    5. Fischman SL
    (1978) In vitro antiplaque properties of a series of alkyl bis(biguanides). J Med Chem 21:828–829.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Cozzarelli NR
    (1977) The mechanism of action of inhibitors of DNA synthesis. Annu Rev Biochem 46:641–668.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Doughty-Shenton D,
    2. Joseph JD,
    3. Zhang J,
    4. Pagliarini DJ,
    5. Kim Y,
    6. Lu D,
    7. Dixon JE, and
    8. Casey PJ
    (2010) Pharmacological targeting of the mitochondrial phosphatase PTPMT1. J Pharmacol Exp Ther 333:584–592.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Eletr S and
    2. Inesi G
    (1972) Phospholipid orientation in sarcoplasmic membranes: spin-label ESR and proton MNR studies. Biochim Biophys Acta 282:174–179.
    OpenUrlPubMed
  10. ↵
    1. Fill M and
    2. Copello JA
    (2002) Ryanodine receptor calcium release channels. Physiol Rev 82:893–922.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Garcia de Mateos-Verchere J,
    2. Vaugeois JM,
    3. Naudin B, and
    4. Costentin J
    (1998) Behavioural and neurochemical evidence that the antimicrobial agent oxolinic acid is a dopamine uptake inhibitor. Eur Neuropsychopharmacol 8:255–259.
    OpenUrlPubMed
  12. ↵
    1. Gleckman R,
    2. Alvarez S,
    3. Joubert DW, and
    4. Matthews SJ
    (1979) Drug therapy reviews: oxolinic acid. Am J Hosp Pharm 36:1077–1079.
    OpenUrlPubMed
  13. ↵
    1. Kolb ME,
    2. Horne ML, and
    3. Martz R
    (1982) Dantrolene in human malignant hyperthermia. Anesthesiology 56:254–262.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Laver DR and
    2. van Helden DF
    (2011) Three independent mechanisms contribute to tetracaine inhibition of cardiac calcium release channels. J Mol Cell Cardiol 51:357–369.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Lehnart SE,
    2. Mongillo M,
    3. Bellinger A,
    4. Lindegger N,
    5. Chen BX,
    6. Hsueh W,
    7. Reiken S,
    8. Wronska A,
    9. Drew LJ,
    10. Ward CW, et al.
    (2008) Leaky Ca2+ release channel/ryanodine receptor 2 causes seizures and sudden cardiac death in mice. J Clin Invest 118:2230–2245.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Ma J
    (1993) Block by ruthenium red of the ryanodine-activated calcium release channel of skeletal muscle. J Gen Physiol 102:1031–1056.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Madden TD,
    2. Chapman D, and
    3. Quinn PJ
    (1979) Cholesterol modulates activity of calcium-dependent ATPase of the sarcoplasmic reticulum. Nature 279:538–541.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Martinsen B,
    2. Oppegaard H,
    3. Wichstrøm R, and
    4. Myhr E
    (1992) Temperature-dependent in vitro antimicrobial activity of four 4-quinolones and oxytetracycline against bacteria pathogenic to fish. Antimicrob Agents Chemother 36:1738–1743.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Mead FC and
    2. Williams AJ
    (2004) Electrostatic mechanisms underlie neomycin block of the cardiac ryanodine receptor channel (RyR2). Biophys J 87:3814–3825.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Meissner G
    (1994) Ryanodine receptor/Ca2+ release channels and their regulation by endogenous effectors. Annu Rev Physiol 56:485–508.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Murayama T,
    2. Kurebayashi N,
    3. Ogawa H,
    4. Yamazawa T,
    5. Oyamada H,
    6. Suzuki J,
    7. Kanemaru K,
    8. Oguchi K,
    9. Iino M, and
    10. Sakurai T
    (2016) Genotype-phenotype correlations of malignant hyperthermia and central core disease mutations in the central region of the RYR1 channel. Hum Mutat 37:1231–1241.
    OpenUrlCrossRef
  22. ↵
    1. Murayama T,
    2. Kurebayashi N,
    3. Yamazawa T,
    4. Oyamada H,
    5. Suzuki J,
    6. Kanemaru K,
    7. Oguchi K,
    8. Iino M, and
    9. Sakurai T
    (2015) Divergent activity profiles of type 1 ryanodine receptor channels carrying malignant hyperthermia and central core disease mutations in the amino-terminal region. PLoS One 10:e0130606.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Ogawa Y
    (1994) Role of ryanodine receptors. Crit Rev Biochem Mol Biol 29:229–274.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Palade P
    (1987) Drug-induced Ca2+ release from isolated sarcoplasmic reticulum. II. Releases involving a Ca2+-induced Ca2+ release channel. J Biol Chem 262:6142–6148.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Priori SG and
    2. Chen SR
    (2011) Inherited dysfunction of sarcoplasmic reticulum Ca2+ handling and arrhythmogenesis. Circ Res 108:871–883.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Rebbeck RT,
    2. Essawy MM,
    3. Nitu FR,
    4. Grant BD,
    5. Gillispie GD,
    6. Thomas DD,
    7. Bers DM, and
    8. Cornea RL
    (2017) High-throughput screens to discover small-molecule modulators of ryanodine receptor calcium release channels. SLAS Discov 22:176–186.
    OpenUrlPubMed
  27. ↵
    1. Robinson R,
    2. Carpenter D,
    3. Shaw MA,
    4. Halsall J, and
    5. Hopkins P
    (2006) Mutations in RYR1 in malignant hyperthermia and central core disease. Hum Mutat 27:977–989.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Sebestík J,
    2. Hlavácek J, and
    3. Stibor I
    (2007) A role of the 9-aminoacridines and their conjugates in a life science. Curr Protein Pept Sci 8:471–483.
    OpenUrlPubMed
  29. ↵
    1. Suzuki J,
    2. Kanemaru K,
    3. Ishii K,
    4. Ohkura M,
    5. Okubo Y, and
    6. Iino M
    (2014) Imaging intraorganellar Ca2+ at subcellular resolution using CEPIA. Nat Commun 5:4153.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Treves S,
    2. Jungbluth H,
    3. Muntoni F, and
    4. Zorzato F
    (2008) Congenital muscle disorders with cores: the ryanodine receptor calcium channel paradigm. Curr Opin Pharmacol 8:319–326.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Uehara A,
    2. Murayama T,
    3. Yasukochi M,
    4. Fill M,
    5. Horie M,
    6. Okamoto T,
    7. Matsuura Y,
    8. Uehara K,
    9. Fujimoto T,
    10. Sakurai T, et al.
    (2017) Extensive Ca2+ leak through K4750Q cardiac ryanodine receptors caused by cytosolic and luminal Ca2+ hypersensitivity. J Gen Physiol 149:199–218.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Watanabe H,
    2. Chopra N,
    3. Laver D,
    4. Hwang HS,
    5. Davies SS,
    6. Roach DE,
    7. Duff HJ,
    8. Roden DM,
    9. Wilde AA, and
    10. Knollmann BC
    (2009) Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med 15:380–383.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Yip KW,
    2. Ito E,
    3. Mao X,
    4. Au PY,
    5. Hedley DW,
    6. Mocanu JD,
    7. Bastianutto C,
    8. Schimmer A, and
    9. Liu FF
    (2006) Potential use of alexidine dihydrochloride as an apoptosis-promoting anticancer agent. Mol Cancer Ther 5:2234–2240.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Yoshizaki Y,
    2. Mori T,
    3. Ishigami-Yuasa M,
    4. Kikuchi E,
    5. Takahashi D,
    6. Zeniya M,
    7. Nomura N,
    8. Mori Y,
    9. Araki Y,
    10. Ando F, et al.
    (2017) Drug-repositioning screening for Keap1-Nrf2 binding inhibitors using fluorescence correlation spectroscopy. Sci Rep 7:3945.
    OpenUrl
  35. ↵
    1. Zhou Q,
    2. Xiao J,
    3. Jiang D,
    4. Wang R,
    5. Vembaiyan K,
    6. Wang A,
    7. Smith CD,
    8. Xie C,
    9. Chen W,
    10. Zhang J, et al.
    (2011) Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca2+ release. Nat Med 17:1003–1009.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleArticle

High-Throughput Screening for Ryanodine Receptor Inhibitors

Takashi Murayama, Nagomi Kurebayashi, Mari Ishigami-Yuasa, Shuichi Mori, Yukina Suzuki, Ryunosuke Akima, Haruo Ogawa, Junji Suzuki, Kazunori Kanemaru, Hideto Oyamada, Yuji Kiuchi, Masamitsu Iino, Hiroyuki Kagechika and Takashi Sakurai
Molecular Pharmacology July 1, 2018, 94 (1) 722-730; DOI: https://doi.org/10.1124/mol.117.111468
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

Advertisement